PRA Health Sciences’ wholly-owned subsidiary, Symphony Health, has launched a ‘first of its kind’ national market measurement solution integrating prescriber, patient, and payer insights.
The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.
To improve patient safety and reduce risk, Elsevier is developing an improved drug-drug interaction risk calculator in collaboration with several pharma partners, including Boehringer Ingelheim, Eli Lilly, and Servier.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
InsightRX raises $10m in a Series A funding round to further develop its treatment individualization platform and broaden the therapeutic areas in which it’s applicable.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
Signant Health is piloting the use of eConsent in a ‘landmark’ study in China, the successful completion of which will encourage further adoption of the technology across the Asia Pacific region, says VP.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.
In response to demand for flexibility, Cromsource has consolidated its hybrid services model to provide customers with an alternative to fully outsourced or functional service provider (FSP) models.
The digital health company AMRA has entered into an exclusive agreement with the largest imaging CRO in Japan as part of its work to provide ‘critical informatics’ to the drug development industry.
